1 Ocak 2015 Dergi makalesi Açık Erişim

Erin, Nuray; Nizam, Esra; Tanriover, Gamze; Koksoy, Sadi

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 76477, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Akdeniz Univ, Sch Med, Dept Med Pharmacol, TR-07070 Antalya, Turkey", 
      "name": "Erin, Nuray"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Akdeniz Univ, Sch Med, Dept Med Pharmacol, TR-07070 Antalya, Turkey", 
      "name": "Nizam, Esra"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Akdeniz Univ, Sch Med, Dept Histol & Embryol, TR-07070 Antalya, Turkey", 
      "name": "Tanriover, Gamze"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Akdeniz Univ, Sch Med, Dept Med Microbiol, TR-07070 Antalya, Turkey", 
      "name": "Koksoy, Sadi"
    }
  ], 
  "datePublished": "2015-01-01", 
  "description": "CXCR2 interacts with a wide range of chemokines and CXCR2 antagonists may have therapeutic value for treatment-resistant metastatic carcinomas. We aimed to explore regulation of activity of CXCR2 and its ligand, MIP-2, in metastatic breast carcinoma. We used mouse breast carcinoma cells metastasize to brain (4TBM), liver (4TLM), and heart (4THM) and explored the extra- and intracellular mechanisms effecting MIP-2 secretion using CXCR2 antagonist and inhibitors of downstream signaling molecules. 4TBM, 4TLM, and 4THM cells include cancer stem cell features and metastasize extensively. We also determined kinetics of MIP-2 secretion in 4T1 and non-metastatic 67NR mouse breast carcinoma cells. We found that there is an autocrine-inhibition of MIP-2 secretion. Specifically, metastatic cells selectively express CXCR2 only, and not CXCR1 and attenuating CXCR2 activity with SB225002 increased MIP-2 secretion. This may be due to the inhibition of protein kinase C (PKC) activity since RO318220; a specific inhibitor of PKC also increased MIP-2 secretion. Attenuating CXCR2 activity with SB225002, otherwise suppressed proliferation of 4THM and 4TBM cells. Tumor explants and cancer-associated fibroblasts obtained from 4TLM, 4THM, and 4TBM primary tumors secreted high levels of MIP-2. Surprisingly, CXCR2 expression was low in 4TLM cells demonstrating that liver metastatic cells might be resistant to the anti-tumoral effects of CXCR2 antagonists. Our results demonstrated that resistance to anti-proliferative effects of CXCR2 may also arise from feedback increases in MIP-2 secretion. Activation of PI3 K pathway augments MIP-2 secretion, hence possible resistance to the antitumor effects of CXCR2 antagonists might be prevented with inhibitors of PI3 K.", 
  "headline": "Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists", 
  "identifier": 76477, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists", 
  "url": "https://aperta.ulakbim.gov.tr/record/76477"
}